Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Treatment.com International ( (TSE:TRUE) ).
Rocket Doctor Inc. has partnered with Melanoma Canada to improve access to follow-up care for patients identified as at-risk during mobile skin cancer screenings across Canada. This collaboration aims to bridge the care gap for individuals without a family doctor by providing timely access to Rocket Doctor’s virtual care platform, thereby increasing patient visits and reinforcing the company’s mission to enhance equitable access to healthcare.
Spark’s Take on TSE:TRUE Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUE is a Underperform.
Treatment.com International is struggling financially, with persistent losses and negative cash flow overshadowing recent revenue growth. The stock is technically weak, and valuation metrics highlight its unprofitable status. However, recent corporate events, including strategic acquisitions and partnerships, provide some potential for future growth, although they have not yet addressed the core financial challenges.
To see Spark’s full report on TSE:TRUE stock, click here.
More about Treatment.com International
Rocket Doctor Inc. is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, focusing on underserved and remote communities across North America.
Average Trading Volume: 125,101
Technical Sentiment Signal: Sell
Current Market Cap: C$27.26M
Find detailed analytics on TRUE stock on TipRanks’ Stock Analysis page.